Trevi Therapeutics initiated with a Buy at JonesResearch

JonesResearch initiated coverage of Trevi Therapeutics with a Buy rating and $7 price target. Trevi is a clinical-stage biopharmaceutical company with its lead asset Haduvio in development for the treatment of chronic cough in idiopathic pulmonary fibrosis, the analyst tells investors in a research note. The analyst is bullish on Trevi based on the firm’s review of the "profound antitussive effects" of Haduvio shown to date and its "best-in-class, first-to-market potential" in IPF.